Building Trust in Healthcare with Immediate Response to Patient Enquiries

On World Patient Safety Day, we want to highlight the essential role of Medical Information (MI) role in building trust and ensuring patient safety. At PLG, we support the life science industry by providing a ready response and comprehensive Medical Information (MI) services. We offer 24/7 coverage, call monitoring, and crisis management support for pharmaceuticals, biologics, advanced therapies, medical devices, cosmetics, and food supplement companies.

 

Re-Energizing for our Growth Plan

Our Chief Commercial Officer, Charlène TRAVERS-CHEVALIER., and Commercial Director, Hélène Masset, had the pleasure of hosting a Breakfast Workshop session titled “From xEVMPD to IDMP” at our Paris HQ. With more than 30 participants from various backgrounds, the event was a resounding success, sparking insightful discussions and fostering collaboration among industry peers. The transition from xEVMPD to IDMP is a pivotal journey for organizations working within regulatory and pharmacovigilance frameworks. Our workshop aimed to demystify the process and provide participants with actionable insights to drive their organization forward.

 

Artificial Intelligence Applied to Medicine: Regulatory Challenges Discussion at FarmaForum

Aymeric Lebon, our Medtech Commercial Director at ProductLife Group, participated in a thought-provoking roundtable discussion alongside industry experts.
The roundtable focused on the transformative role of Artificial Intelligence and the regulatory challenges it presents for the future of health care. The discussion highlighted AI’s potential to improve medicine and emphasized the importance of addressing the regulatory challenges that come with these advancements.

Day 1 Speaking Session at the World Drug Safety Congress Europe

Lucy Green, PLG’s Director of Local Safety PV, and Minyar Chelly, PLG’s Director of EU QPPV-LSO and Medical Writing, delivered an insightful session on navigating global and local PV compliance. They offered practical solutions to some of the most common challenges faced in the field. We were thrilled not only by the large turnout but also by the incredible level of engagement from the audience. Special thanks to representatives from Ipsen, Novo Nordisk, Astellas Pharma, UCB, Ferring Pharmaceuticals, and many others for being part of this experience.

 

Highlights from the Brain Organoids Panel, presented by our Research & Innovation Director

The recent panel discussion brought together 20 stakeholders, each with either extensive experience in brain organoid research and development or a keen interest in exploring its social and public perception. This convergence of perspectives resulted in a highly engaging exchange, where we looked into the latest groundbreaking research, like organoid biocomputing intelligence and its ethics. The conversation also touched on the ethical complexities surrounding this emerging field. The new ethical framework from the EU-funded Hybrida project was introduced, offering practical tools to navigate organoid research responsibly.


New partnership between PLG and Opyl, a AI-Driven Biostatistical Validation Leader

This collaboration marks our commitment to leveraging AI while maintaining our dedication to quality, regulatory compliance and precision in everything we do. Our experts work with industry SMEs and business owners to explore A.I benefits and limits in their specific context, ranging from AI architecture to data science, devOps and CSV. Our technology-agnostic approach ensures that we select the best technical and scientific methods to address the needs of our operations and answer the key data challenges faced by our clients.


Highlighting the Critical Role of Readability Testing in Patient Information Leaflet

Are patient information leaflets (PILs) clear for everyone to understand?
It’s crucial for patient safety that patient information leaflets are easy to read. Providing clear instructions can significantly enhance patient compliance with their treatment plans while also fulfilling important regulatory requirements.
At PLG, our team specializes in tailoring PILs to meet these standards and ensure patients can easily understand and adhere to the provided instructions.
As the field continues to advance, addressing these challenges will be essential for bringing more life-saving gene therapies to patients.

 

Register to our news and events

Go to our Events to register
Go to our News to get insights

October 2024 Monthly Newsletter